Post-Cardiac Arrest Care — Part 2: Targeted Temperature Management

1. Historical Evolution of Temperature Management After Cardiac Arrest

The concept of therapeutic hypothermia for neuroprotection after cardiac arrest has undergone significant evolution over the past two decades, shaped by a series of landmark clinical trials that have progressively refined our understanding of optimal temperature targets and the mechanisms by which temperature management benefits (or fails to benefit) post-arrest patients.^{1 2 3 4 5}

1.1 Timeline of Key Evidence

1.2 Landmark Trial Details

The HACA Trial (2002)¹

• Full title: “Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest”
• Design: Multicenter, randomized, assessor-blinded; 275 patients
• Population: Adults with witnessed OHCA due to ventricular fibrillation
• Intervention: Target temperature 32–34°C for 24 hours vs. standard normothermic care
• Primary outcome: Favorable neurologic outcome at 6 months (CPC 1 or 2): 55% (hypothermia) vs. 39% (normothermia); RR 1.40 (95% CI 1.08–1.81)
• Mortality at 6 months: 41% (hypothermia) vs. 55% (normothermia); RR 0.74 (95% CI 0.58–0.95)
• NNT: 6 for favorable neurologic outcome; 7 for survival
• Limitations: No active temperature management in the control group (many patients were febrile); only VF arrests included; small sample size by current standards; concern about self-fulfilling prophecy in neuroprognostication
• Historical significance: Along with the concurrent Bernard et al. study, this trial established induced hypothermia as the standard of care for post-arrest neuroprotection, leading to a Class I recommendation across all major guidelines

The Bernard et al. Study (2002)²

• Design: Single-center, quasi-randomized (by date); 77 patients
• Population: Adults with OHCA due to VF
• Intervention: Target temperature 33°C for 12 hours vs. normothermia
• Primary outcome: Good neurologic outcome (discharge to home or rehabilitation): 49% (hypothermia) vs. 26% (normothermia); P = 0.046
• Mortality: 51% (hypothermia) vs. 68% (normothermia); P = 0.145 (not statistically significant)
• Limitations: Small, single-center, quasi-randomized; short cooling duration (12 hours)

The TTM Trial — TTM1 (2013)³

• Full title: “Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest”
• Design: Multicenter, randomized, assessor-blinded; 950 patients across 36 ICUs in Europe and Australia
• Population: Adults with OHCA (presumed cardiac cause) with any initial rhythm, comatose after ROSC
• Intervention: Target temperature 33°C for 28 hours vs. target temperature 36°C for 28 hours, followed by controlled rewarming and mandatory fever prevention to 37.5°C through 72 hours
• Primary outcome: All-cause mortality at end of trial: 50% (33°C) vs. 48% (36°C); HR 1.06 (95% CI 0.89–1.28; P = 0.51)
• Secondary outcome: Poor neurologic outcome at 180 days (CPC 3–5): 54% (33°C) vs. 52% (36°C); RR 1.02 (95% CI 0.88–1.16; P = 0.78)
• Key insight: Both groups received active temperature management; the control group was NOT allowed to become febrile. This is fundamentally different from HACA, where the control group received no active temperature management and many patients developed fever.
• Impact: Demonstrated that 33°C offered no benefit over 36°C when both groups received active temperature control and fever prevention. Many centers shifted from 33°C to 36°C targets.

The HYPERION Trial (2019)⁴

• Full title: “Targeted Temperature Management for Cardiac Arrest with Nonshockable Rhythm”
• Design: Multicenter, randomized, open-label with blinded outcome assessment; 584 patients across 25 ICUs in France
• Population: Adults with cardiac arrest (OHCA or IHCA) and non-shockable initial rhythm (PEA or asystole), comatose after ROSC
• Intervention: Target temperature 33°C for 24 hours vs. targeted normothermia (37°C) for 48 hours
• Primary outcome: Favorable neurologic outcome at 90 days (CPC 1 or 2): 10.2% (hypothermia) vs. 5.7% (normothermia); difference 4.5 percentage points (95% CI 0.1–8.9; P = 0.04)
• Mortality at 90 days: 81.3% (hypothermia) vs. 83.2% (normothermia); not significant
• Key insights:
  • Absolute benefit was modest (NNT = 22) but statistically significant
  • Overall prognosis in non-shockable rhythms remains poor regardless of temperature strategy
  • This is the only randomized trial to demonstrate benefit of hypothermia specifically in non-shockable rhythms
  • The control group targeted 37°C (not fever prevention), leaving open the question of whether benefit came from cooling or from fever avoidance
• Limitations: Open-label design; modest sample size; very high mortality in both groups

The TTM2 Trial (2021)⁵

• Full title: “Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest”
• Design: Multicenter, randomized, assessor-blinded; 1,900 patients across 61 sites in 14 countries — the largest TTM trial to date
• Population: Adults with OHCA (any cause), comatose after ROSC
• Intervention: Targeted hypothermia at 33°C for 28 hours followed by controlled rewarming vs. early treatment of fever (target ≤37.8°C; active cooling initiated only if temperature reached 37.8°C)
• Primary outcome: All-cause mortality at 6 months: 50% (hypothermia) vs. 48% (normothermia); RR 1.04 (95% CI 0.94–1.14; P = 0.37)
• Secondary outcome: Poor functional outcome at 6 months (mRS 4–6): 55% (hypothermia) vs. 55% (normothermia); RR 1.00 (95% CI 0.92–1.09)
• Subgroup analyses: No benefit of hypothermia in any pre-specified subgroup (including shockable vs. non-shockable rhythm, age, sex, time to ROSC)
• Adverse events: More arrhythmias with hemodynamic compromise in the hypothermia group (24% vs. 17%; P < 0.001)
• Key insight: Active hypothermia at 33°C provided no benefit over targeted normothermia with active fever treatment. This trial, combined with TTM1, strongly suggests that the benefit observed in HACA was from fever prevention rather than from cooling itself.
• Impact on practice: Shifted the standard of care from mandatory hypothermia toward active fever prevention as the minimum standard, with hypothermia (32–36°C) remaining an acceptable option but no longer considered superior.

2. Current Recommendations — Temperature Targets

Based on the totality of evidence, the current international consensus reflects significant evolution from the original hypothermia mandate.^{6 7 8 9}

2.1 Summary of Current Guideline Recommendations

2.2 Practical Decision Framework

2.3 Key Principles

1. Fever prevention is the minimum standard. All comatose post-arrest patients must have active temperature monitoring and intervention to prevent fever (temperature > 37.7°C) for at least 72 hours after ROSC.
2. If hypothermia is chosen, target a constant temperature within the 32–36°C range (most commonly 33°C or 36°C). Avoid temperature fluctuations.
3. Duration of active temperature control: Minimum 24 hours of hypothermia (if used); fever prevention should continue for at least 72 hours total from ROSC.
4. Controlled rewarming is mandatory if hypothermia was used: no faster than 0.25–0.5°C per hour.
5. Temperature management should not be delayed for diagnostic or interventional procedures (including coronary angiography).

3. TTM Protocol — Phases and Parameters

3.1 Phase Overview

3.2 Induction Phase — Detailed Protocol

Timing:

• Initiate temperature management as soon as possible after ROSC
• Do not delay for coronary angiography, CT scanning, or other procedures
• Begin cooling in the emergency department, during transport, or upon ICU arrival

Cold intravenous saline:

• Current guidance: The routine use of large-volume (30 mL/kg) cold (4°C) intravenous saline for prehospital induction of hypothermia is not recommended, based on the RINSE and PARAMEDIC2 trial data showing potential for harm (rearrest, pulmonary edema) without clear benefit.¹⁰
• Small-volume cold crystalloid (e.g., 500–1000 mL) may be used as an adjunct to device-based cooling but should not be the primary cooling method

Device-based cooling (see Section 4): Initiate as the primary cooling modality

Sedation and analgesia:

• Essential to prevent shivering and provide patient comfort
• Propofol (5–80 μg/kg/min) + fentanyl (25–200 μg/h) or remifentanil infusion is a common regimen
• Alternative: midazolam (1–10 mg/h) + fentanyl if hemodynamics do not tolerate propofol
• Dexmedetomidine may be used as an adjunct (does not reliably suppress shivering at high levels)
• Neuromuscular blockade may be necessary if shivering is refractory (see Section 5)

3.3 Maintenance Phase — Detailed Protocol

Temperature stability:

• Target temperature should be maintained within ±0.3°C of the set point
• Continuous temperature monitoring (esophageal probe preferred; see Section 7)
• Device-based cooling systems with feedback loops provide the most stable temperature control

Monitoring during maintenance:

Blood gas interpretation during hypothermia:

• Use alpha-stat (temperature-uncorrected) blood gas management — this is the standard approach
• Do not correct ABG values for the patient’s actual temperature; use the values reported at 37°C by the analyzer
• Alpha-stat management maintains normal intracellular pH and enzyme function

3.4 Rewarming Phase — Detailed Protocol

Rewarming is a high-risk period characterized by hemodynamic instability, electrolyte shifts, and rebound inflammation. Controlled, slow rewarming is critical.^{6 7}

Rewarming rate:

Critical monitoring during rewarming:

4. Methods of Cooling

4.1 Comparison of Cooling Modalities

4.2 Practical Recommendations

1. For centers performing TTM at 33°C: Intravascular cooling or surface gel pad systems with automated feedback control are preferred due to superior temperature precision and controlled rewarming capability.
2. For active fever prevention (normothermia strategy): Surface cooling systems (gel pads or blankets) are adequate; intravascular cooling is not typically necessary for fever prevention alone.
3. Ice packs and cold saline alone are not adequate for maintenance of any temperature target — they may be used only as temporary bridges until definitive cooling devices are available.
4. Prehospital cold saline infusion is not recommended for routine use based on evidence of potential harm without benefit.¹⁰

5. Shivering Management

Shivering is the primary physiological barrier to effective cooling and occurs in the majority of patients undergoing TTM at hypothermic targets. Shivering increases metabolic rate, oxygen consumption, and CO2 production, counteracting the neuroprotective goals of temperature management. A systematic, stepwise approach to shivering prevention and treatment is essential.^{7 11}

5.1 Bedside Shivering Assessment Scale (BSAS)

The BSAS provides a standardized, validated tool for quantifying shivering severity at the bedside.¹¹

Monitoring frequency: Assess BSAS every 1–2 hours during TTM induction and maintenance. Intervention should be initiated at BSAS ≥ 1 to prevent escalation.

5.2 Stepwise Shivering Management Protocol

The following protocol provides a stepwise escalation from non-pharmacologic interventions through pharmacologic therapies to neuromuscular blockade. Each step is added sequentially; lower tiers should be continued as higher tiers are added.^{7 11}

5.3 Key Principles of Shivering Management

• Prevention is more effective than treatment. Initiate skin counterwarming, acetaminophen, and sedation prophylactically at the time of TTM initiation.
• Multimodal approach. Combine agents from different tiers rather than maximizing a single agent.
• Continuous EEG is mandatory if neuromuscular blockade is used, as clinical seizure detection is impossible in paralyzed patients.
• Document BSAS regularly to track response to interventions and guide escalation/de-escalation.
• Shivering is most pronounced during induction (when the gap between skin/core temperature and the thermoregulatory set point is greatest). Aggressive prophylaxis during induction is essential.

6. Complications of TTM

Temperature management, particularly at hypothermic targets, is associated with several physiological consequences that require proactive monitoring and management.^{6 7 8}

6.1 Cardiovascular Complications

6.2 Metabolic and Electrolyte Complications

6.3 Hematologic Complications

6.4 Infectious Complications

6.5 Other Complications

7. Temperature Monitoring

Accurate, continuous core temperature monitoring is essential for safe and effective TTM. The choice of monitoring site affects the precision and reliability of temperature measurement.⁷

7.1 Temperature Monitoring Site Comparison

7.2 Practical Recommendations

• Preferred: Esophageal temperature probe in all intubated post-arrest patients undergoing TTM
• Acceptable alternative: Bladder temperature catheter (ensure adequate urine output for accuracy)
• Use two sites when possible (e.g., esophageal + bladder) for cross-verification, particularly during rewarming
• Confirm probe position after placement (esophageal probe should be in the lower third of the esophagus, approximately 35–40 cm from the nares)
• Peripheral temperature sites (tympanic, axillary, temporal artery) are not adequate for TTM management

8. Special Populations

8.1 Non-Shockable Rhythms (PEA/Asystole)

• Non-shockable initial rhythms account for approximately 70–80% of OHCA and the majority of IHCA
• Overall prognosis is substantially worse than shockable rhythms (survival to discharge: 5–15% for OHCA with non-shockable rhythm vs. 25–35% for shockable rhythm)
• The HYPERION trial provides the strongest evidence for hypothermia benefit in this population, though the absolute benefit was modest (NNT = 22)⁴
• The TTM2 subgroup analysis did not demonstrate benefit of hypothermia at 33°C vs. normothermia in the non-shockable rhythm subgroup, though the study was not powered for subgroup analyses⁵
• Current recommendation: Active fever prevention is the minimum standard. Hypothermia (33°C for 24 hours) is a reasonable option, particularly in institutions where it is already the established protocol.

8.2 In-Hospital Cardiac Arrest (IHCA)

• IHCA accounts for approximately 200,000–300,000 events annually in the United States
• No large randomized trial has specifically studied TTM in IHCA populations
• Observational data are mixed; some registries suggest benefit from fever prevention but not from active hypothermia
• Current recommendation: Active fever prevention for ≥72 hours. Hypothermia (32–36°C) may be considered on a case-by-case basis, particularly if the arrest was witnessed, a shockable rhythm was present, and ROSC was achieved rapidly.

8.3 Pregnancy

• Post-arrest TTM in pregnant patients must balance maternal neuroprotection with fetal safety
• Hypothermia at 32–36°C has been used in pregnant post-arrest patients in case reports and small series without consistent evidence of fetal harm
• Continuous fetal heart rate monitoring should be performed when feasible
• Fetal bradycardia is expected during maternal hypothermia and does not necessarily indicate fetal distress
• Obstetric and neonatal teams should be involved from the time of ROSC
• Current recommendation: TTM should not be withheld from pregnant post-arrest patients. Multidisciplinary team involvement is essential.

8.4 Patients Already Hypothermic at Presentation

• Patients presenting with accidental hypothermia who then arrest require rewarming as part of resuscitation
• Do not re-cool patients who were already hypothermic at the time of arrest
• If ROSC is achieved and the patient’s temperature is within the TTM target range (e.g., 33–36°C), maintain that temperature for 24 hours before controlled rewarming
• Neuroprognostication timelines should be adjusted to account for the duration of hypothermia

9. TTM Order Set — Summary Table

The following table provides a concise reference for all TTM protocol parameters:

References